Key Performance
More- Earnings Score: N/A
- Momentum Score: 28
- True Yield: N/A
- Financial Health Score: N/A
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
Instil Bio (Nasdaq: TIL) reported Q1 2026 results with a cash position of $74.7 million, sufficient to fund operations beyond 2027. The company is actively evaluating acquisition and in-licensing opportunities to build its pipeline. R&D expenses decreased to $0.7 million from $5.4 million year-over-year, while net loss per share improved to $0.62 from $4.32.
05/15/2026, 7:00 AM • GlobeNewswire
Pomerantz LLP announced investigations into securities fraud claims on behalf of investors in three biotech companies. Zenas BioPharma's stock plummeted 51.86% following disappointing Phase 3 trial results for obexelimab, with the CEO acknowledging the drug's efficacy fell short of expectations, triggering an additional 8.49% decline. Similar investigations were initiated for Instil Bio and Corcept Therapeutics.
01/13/2026, 3:53 PM • GlobeNewswire
Pomerantz LLP is investigating potential securities fraud claims on behalf of investors in AST SpaceMobile, Instil Bio, and Corcept Therapeutics. The investigation into AST was triggered by a Scotiabank downgrade to Sell on January 7, 2026, citing competition from SpaceX's Starlink, slow customer adoption, and satellite launch delays. AST's stock fell 12.06% following the downgrade.
01/13/2026, 3:53 PM • GlobeNewswire
Pomerantz LLP is investigating potential securities fraud claims on behalf of investors in First Solar, Instil Bio, and Corcept Therapeutics. First Solar's stock fell 10.29% on January 7, 2026, following a Jefferies downgrade to Hold due to lowered guidance, significant de-bookings, margin compression, and limited deployment opportunities expected in 2026.
01/13/2026, 3:53 PM • GlobeNewswire
Instil Bio Posts Wider Loss in Q2
Instil Bio reported a wider loss in Q2 2025, with Non-GAAP EPS of $(2.88), missing analyst expectations. The company increased R&D spending to $6.7 million and received FDA clearance for its lead drug candidate '2510, with plans to launch a U.S. clinical trial before year-end.
08/13/2025, 7:09 AM • The Motley Fool
Over 180 companies are developing 250+ bispecific antibodies targeting complex chronic diseases like cancer and autoimmune disorders, with innovative dual-targeting molecules offering superior therapeutic precision and efficacy.
07/07/2025, 1:00 PM • GlobeNewswire
Peers
Statistics
MoreInformation as of 06/03/2026
Company Profile
Instil Bio, Inc., a biopharmaceutical company, focuses on identifying and advancing therapeutic opportunities. It seeks to in-license or acquire and develop additional novel therapeutic candidates in diseases with significant unmet medical need. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.